NEW YORK, April 16, 2013 /PRNewswire/ -- Twenty Swiss-based biotech industry companies and organizations are highlighting their expertise at the Swiss Pavilion (Booth 5454, Hall A) during the BIO International Convention April 22-25 in Chicago, reports Daniel Bangser, Director North America for Switzerland Trade & Investment Promotion. Some 150 additional representatives of biotech firms in Switzerland are expected to attend.
Advances and Emerging Trends in the Swiss Biotech Market, with Nic Alexakis, CEO of the Swiss Biotech Association, and Juergen Regenold, CEO of regulanet (Monday Apr 22, 10:00 AM - 10:45 AM)
Summary of the Swiss Biotech Report 2013
For 2012, net sales in the Swiss biotech industry remained stable despite the European debt crisis. Biotech activities of Swiss companies remained high as revealed by the number of products in the clinical pipeline.
- Net sales amounted to a total of CHF 4,642 billion, about 1% less than the previous year.
- Capital investments in Swiss biotech companies amounted to approximately CHF 260 million. Though significantly lower than 2011, the overall picture looks similar when debt financing is removed from the analysis.
- The number of biotech firms increased slightly from the previous year to 250 developers and suppliers. The number of employees totals over 13,700.
"A well-functioning transfer of knowledge and technology combined with a high degree of innovation are key components of Switzerland's prosperity," Mr. Bangser said. "Swiss biotech companies play an important role in this process. Success is largely due to the excellent cooperation between universities, research networks, government institutions and the many small and large biotech companies. The Swiss Biotech Association will continue to support and promote this cooperation in the coming years with a broad range of measures."
SOURCE Switzerland Trade & Investment Promotion